| Target Price | $51.00 |
| Price | $45.44 |
| Potential | 12.24% |
| Number of Estimates | 18 |
| 18 Analysts have issued a price target Exelon 2026 . The average Exelon target price is $51.00. This is 12.24% higher than the current stock price. The highest price target is $59.85 31.71% , the lowest is $42.00 7.58% . | |
| A rating was issued by 24 analysts: 12 Analysts recommend Exelon to buy, 10 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Exelon stock has an average upside potential 2026 of 12.24% . Most analysts recommend the Exelon stock at Purchase. |
19 Analysts have issued a sales forecast Exelon 2025 . The average Exelon sales estimate is $24.4b . This is 2.49% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $25.9b 9.13% , the lowest is $23.0b 3.43% .
This results in the following potential growth metrics:
| 2024 | $23.0b | 5.99% |
|---|---|---|
| 2025 | $24.4b | 5.77% |
| 2026 | $25.3b | 3.77% |
| 2027 | $26.1b | 3.21% |
| 2028 | $26.7b | 2.33% |
| 2029 | $27.4b | 2.79% |
| 2030 | $27.2b | 0.87% |
14 Analysts have issued an Exelon EBITDA forecast 2025. The average Exelon EBITDA estimate is $8.9b . This is 6.46% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $9.6b 14.67% , the lowest is $8.4b 0.14% .
This results in the following potential growth metrics and future EBITDA Margins:
| 2024 | $7.9b | 5.08% |
|---|---|---|
| 2025 | $8.9b | 12.90% |
| 2026 | $9.6b | 7.70% |
| 2027 | $10.3b | 7.37% |
| 2028 | $10.8b | 5.13% |
| 2029 | $11.5b | 5.88% |
| 2024 | 34.31% | 0.86% |
|---|---|---|
| 2025 | 36.62% | 6.73% |
| 2026 | 38.01% | 3.80% |
| 2027 | 39.54% | 4.03% |
| 2028 | 40.62% | 2.73% |
| 2029 | 41.84% | 3.00% |
21 Exelon Analysts have issued a net profit forecast 2025. The average Exelon net profit estimate is $2.7b . This is 3.51% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.9b 8.65% , the lowest is $2.6b 1.13% .
This results in the following potential growth metrics and future Net Margins:
| 2024 | $2.5b | 5.67% |
|---|---|---|
| 2025 | $2.7b | 11.63% |
| 2026 | $2.9b | 5.11% |
| 2027 | $3.1b | 6.54% |
| 2028 | $3.3b | 6.55% |
| 2029 | $3.5b | 7.31% |
| 2024 | 10.68% | 0.30% |
|---|---|---|
| 2025 | 11.27% | 5.50% |
| 2026 | 11.42% | 1.33% |
| 2027 | 11.79% | 3.24% |
| 2028 | 12.27% | 4.07% |
| 2029 | 12.81% | 4.40% |
21 Analysts have issued a Exelon forecast for earnings per share. The average Exelon EPS is $2.72 . This is 3.42% higher than earnings per share in the financial year 2024. The highest EPS forecast is $2.85 8.37% , the lowest is $2.60 1.14% .
This results in the following potential growth metrics and future valuations:
| 2024 | $2.45 | 4.70% |
|---|---|---|
| 2025 | $2.72 | 11.02% |
| 2026 | $2.86 | 5.15% |
| 2027 | $3.04 | 6.29% |
| 2028 | $3.24 | 6.58% |
| 2029 | $3.48 | 7.41% |
| Current | 17.28 | 9.71% |
|---|---|---|
| 2025 | 16.72 | 3.27% |
| 2026 | 15.91 | 4.84% |
| 2027 | 14.93 | 6.16% |
| 2028 | 14.01 | 6.16% |
| 2029 | 13.06 | 6.78% |
Based on analysts' sales estimates for 2025, the Exelon stock is valued at an EV/Sales of 3.86 and an P/S ratio of 1.89 .
This results in the following potential growth metrics and future valuations:
| Current | 3.96 | 8.49% |
|---|---|---|
| 2025 | 3.86 | 2.49% |
| 2026 | 3.72 | 3.64% |
| 2027 | 3.61 | 3.11% |
| 2028 | 3.52 | 2.28% |
| 2029 | 3.43 | 2.71% |
| 2030 | 3.46 | 0.88% |
| Current | 1.93 | 15.64% |
|---|---|---|
| 2025 | 1.89 | 2.43% |
| 2026 | 1.82 | 3.63% |
| 2027 | 1.76 | 3.11% |
| 2028 | 1.72 | 2.28% |
| 2029 | 1.67 | 2.71% |
| 2030 | 1.69 | 0.88% |
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
➜
Overweight
|
Initiated | Oct 28 2025 |
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 22 2025 |
| Jefferies |
Buy
➜
Buy
|
Unchanged | Oct 15 2025 |
| Keybanc |
Underweight
➜
Underweight
|
Unchanged | Oct 15 2025 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Oct 14 2025 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Oct 10 2025 |
| Evercore ISI Group |
➜
Outperform
|
Initiated | Oct 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Initiated
Wells Fargo:
➜
Overweight
|
Oct 28 2025 |
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Oct 22 2025 |
|
Unchanged
Jefferies:
Buy
➜
Buy
|
Oct 15 2025 |
|
Unchanged
Keybanc:
Underweight
➜
Underweight
|
Oct 15 2025 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Oct 14 2025 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Oct 10 2025 |
|
Initiated
Evercore ISI Group:
➜
Outperform
|
Oct 07 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


